WO2016193919A1 - Forme polymorphe de ledipasvir - Google Patents

Forme polymorphe de ledipasvir Download PDF

Info

Publication number
WO2016193919A1
WO2016193919A1 PCT/IB2016/053215 IB2016053215W WO2016193919A1 WO 2016193919 A1 WO2016193919 A1 WO 2016193919A1 IB 2016053215 W IB2016053215 W IB 2016053215W WO 2016193919 A1 WO2016193919 A1 WO 2016193919A1
Authority
WO
WIPO (PCT)
Prior art keywords
ledipasvir
solvent
solution
mixtures
process according
Prior art date
Application number
PCT/IB2016/053215
Other languages
English (en)
Inventor
Ramakoteswara Rao Jetti
Amit Singh
Satish BEERAVELLY
Sreenivasarao PATHURI
Nagadurgarao BANDI
Original Assignee
Mylan Laboratories Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mylan Laboratories Limited filed Critical Mylan Laboratories Limited
Publication of WO2016193919A1 publication Critical patent/WO2016193919A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne de nouveaux polymorphes stables de ledipasvir désignés comme formes M1, ainsi que des procédés de préparation de ceux-ci.
PCT/IB2016/053215 2015-06-05 2016-06-01 Forme polymorphe de ledipasvir WO2016193919A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2181MU2015 2015-06-05
IN2181/MUM/2015 2015-06-05

Publications (1)

Publication Number Publication Date
WO2016193919A1 true WO2016193919A1 (fr) 2016-12-08

Family

ID=56235857

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2016/053215 WO2016193919A1 (fr) 2015-06-05 2016-06-01 Forme polymorphe de ledipasvir

Country Status (1)

Country Link
WO (1) WO2016193919A1 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013184698A1 (fr) 2012-06-05 2013-12-12 Gilead Sciences, Inc. Formes solides d'un composé antiviral

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013184698A1 (fr) 2012-06-05 2013-12-12 Gilead Sciences, Inc. Formes solides d'un composé antiviral

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CAIRA: "Crystalline Polymorphism of Organic Compounds", TOPICS IN CURRENT CHEMISTRY, SPRINGER, BERLIN, DE, vol. 198, 1 January 1998 (1998-01-01), pages 163 - 208, XP008166276, ISSN: 0340-1022 *

Similar Documents

Publication Publication Date Title
KR101560428B1 (ko) Ｎ-(ｔｅｒｔ-부톡시카르보닐)-3-메틸-ｌ-발릴-(4ｒ)-4-((7-클로로-4-메톡시-1-이소퀴놀리닐)옥시)-ｎ-((1ｒ,2ｓ)-1-((시클로프로필술포닐)카르바모일)-2-비닐시클로프로필)-ｌ-프롤린아미드의 결정질 형태
KR101470715B1 (ko) 다사티닙 다결정체 및 그의 제조방법과 약물 조성물
EP3549932B1 (fr) Nouvelles formes cristallines d'acide {[5-(3-chlorophényl)-3-hydroxypyridine-2-carbonyl]amino} acétique et leur procédé de préparation
US8541443B2 (en) Crystal of diamine derivative and method of producing same
CN115960088A (zh) 一种新型冠状病毒主蛋白酶的抑制剂及其制备方法和用途
WO2012044595A1 (fr) Mésylate de dabigatran étexilate, ses formes solides et leurs procédés de préparation
US10208065B2 (en) Crystalline free bases of C-Met inhibitor or crystalline acid salts thereof, and preparation methods and uses thereof
WO2015138933A1 (fr) Formes à l'état solide de dolutegravir sodium
US10738071B2 (en) Polymorphic forms of sofosbuvir
CN108290882A (zh) 用于治疗呼吸道合胞病毒(rsv)感染的n-[(3-氨基-3-氧杂环丁基)甲基]-2-(2,3-二氢-1,1-二氧代-1,4-苯并噻氮*-4(5h)-基)-6-甲基-4-喹唑啉胺的晶形
WO2016193919A1 (fr) Forme polymorphe de ledipasvir
US20210300950A1 (en) Solid state forms of ixazomib citrate
WO2016157136A1 (fr) Formes cristallines de l'idélalisib
CN112225730A (zh) 一种稠环化合物的晶型、其组合物、制备方法及其应用
US10221185B2 (en) Crystal form of substituted aminopyran derivativek
CN112125910A (zh) 一种阿伐普替尼晶型及其制备方法
CN108069891B (zh) 一类甲基甲胺盐酸盐的a晶型、制备及其应用
EP4349835A1 (fr) Forme cristalline d'hydrate de méthanesulfonate de lazertinib, son procédé de préparation et son utilisation
CN105732596B (zh) N-[3-氯-4-(3-氟苄氧基)苯基]-6-[5-[[2-(甲亚磺酰基)乙基]氨基]甲基]-2-呋喃基]-4-喹唑啉胺多晶型物及其制备方法
CN111484488A (zh) 一种b-raf激酶二聚体抑制剂的稳定结晶形式a
CN117736176A (zh) 雄激素受体拮抗剂的可药用盐及其多晶型物、制备方法和用途
CA2829186A1 (fr) Forme amorphe d'un melange de lopinavir et de ritonavir
CN111484489A (zh) 无定形的b-raf激酶二聚体抑制剂
AU2018201013A1 (en) Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16732336

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16732336

Country of ref document: EP

Kind code of ref document: A1